 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 February 1994 | Volume 120 Issue 3 | Pages 199-206
Objective: To evaluate the efficacy and safety of iloprost, a prostacyclin analog, administered intravenously in patients with Raynaud phenomenon secondary to systemic sclerosis.
Design: Multicenter, randomized, parallel placebo-controlled, double-blind study.
Setting: University medical centers.
Patients: 131 patients with systemic sclerosis (101 women, 30 men) ages 20 to 79 years.
Intervention: Patients were randomly assigned to receive one of two parallel treatments of five daily sequential, 6-hour intravenous infusions of iloprost (0.5 to 2.0 ng/kg per min) or to receive a similar volume of placebo.
Measurements: Frequency of Raynaud attacks, Raynaud severity score, physician's overall rating of treatment effect, and digital cutaneous lesion healing.
Results: Of the 131 patients enrolled, 126 completed the 5-day infusion and 114 (87%) completed at least 6 weeks of follow-up. Sixty-four patients were randomly assigned to receive iloprost and 67 patients, to receive placebo. The mean weekly number of Raynaud attacks decreased 39.1% with iloprost and 22.2% with placebo (P = 0.005). In addition, the mean percentage of improvement in a global Raynaud severity score during the entire 9-week follow-up was greater in patients given iloprost (34.8%) than in those receiving placebo (19.7%) (P = 0.011). The physician's overall rating of treatment effect showed greater improvement with iloprost than with placebo at week 6 (52.4% compared with 27.4%; P = 0.008) and week 9 (60.9% compared with 26.9%; P < 0.001). At week 3, 14.6% more patients receiving iloprost had 50% or more lesions heal compared with those given placebo (95% CI, 0.9% to 30%). During the infusion, 59 (92%) of the patients receiving iloprost had one or more side effects compared with 38 (57%) of the patients receiving placebo.
Conclusion: Iloprost is effective for the short-term palliation of severe Raynaud phenomenon in patients with systemic sclerosis.
Author and Article Information
From The Johns Hopkins University School of Medicine, Baltimore, Maryland; Robert Wood Johnson Medical School, New Brunswick, New Jersey; West Virginia University, Morgantown, West Virginia; University of Pittsburgh, Pittsburgh, Pennsylvania; Thomas Jefferson University, Philadelphia, Pennsylvania; Wayne State University, Detroit, Michigan; UCLA School of Medicine, Los Angeles, California; UCLA San Fernando Valley Program, Granada Hills, California; University of Oregon, Portland, Oregon; University of Chicago, Chicago, Illinois; Bowman Gray School of Medicine, Winston-Salem, North Carolina; State University at New York at Stony Brook, Stony Brook, New York; Berlex Laboratories, Wayne, New Jersey.
ARTICLE
Intravenous Iloprost Infusion in Patients with Raynaud Phenomenon Secondary to Systemic Sclerosis: A Multicenter, Placebo-controlled, Double-Blind Study
Requests for Reprints: Fredrick M. Wigley, MD, The Johns Hopkins University, Division of Molecular and Clinical Rheumatology, 1830 East Monument Street, Suite 7500, Baltimore, MD 21205
Acknowledgments: The authors thank Gwenn Leatherman, RN, Mary J.F. Rykiel, RN, MAS, Linda Ehrlich, RN, MSN, Sue Connaughton, RN, MSN, and Carol Blair, RN, for technical assistance; Robert Lehr, MS, for the statistical analyses; Naomi Marcus, PhD, for assistance in preparing the report; and Shawnice M. Foster for secretarial support.
Grant Support: Funded and coordinated by Berlex Laboratories, whose representatives (WD and JW) participated with the principal investigators in the study design, analysis, and manuscript preparation.
This article has been cited by other articles:
|
|
 |
|
  R. C. Jeffery, C. B. Narshi, and D. A. Isenberg Prevalence, serological features, response to treatment and outcome of critical peripheral ischaemia in a cohort of lupus patients Rheumatology, September 1, 2008; 47(9): 1379 - 1383. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M E Hettema, D Zhang, H Bootsma, and C G M Kallenberg Bosentan therapy for patients with severe Raynaud's phenomenon in systemic sclerosis Ann Rheum Dis, October 1, 2007; 66(10): 1398 - 1399. [Full Text] [PDF]
|
|
|
|
|
|
M. Salvat-Melis, P. H. Carpentier, C. T. Minson, A. Boignard, G. R. McCord, A. Paris, A. Moreau-Gaudry, and J.-L. Cracowski Digital thermal hyperaemia impairment does not relate to skin fibrosis or macrovascular disease in systemic sclerosis Rheumatology, December 1, 2006; 45(12): 1490 - 1496. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Milio, E. Corrado, C. Genova, C. Amato, F. Raimondi, P. L. Almasio, and S. Novo Iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis and the quality of life: a new therapeutic protocol Rheumatology, August 1, 2006; 45(8): 999 - 1004. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. L. Herrick Pathogenesis of Raynaud's phenomenon Rheumatology, May 1, 2005; 44(5): 587 - 596. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. M. Wigley Raynaud's Phenomenon N. Engl. J. Med., September 26, 2002; 347(13): 1001 - 1008. [Full Text] [PDF]
|
|
|
|
 |
|
 A Mathieu, G Sanna, A Mameli, C Pinna, A Vacca, A Cauli, G Passiu, and M Piga Sustained normalization of cerebral blood-flow after iloprost therapy in a patient with neuropsychiatric systemic lupus erythematosus Lupus, January 1, 2002; 11(1): 52 - 56. [Abstract] [PDF]
|
|
|
|
|
|
M. Keberle, H.-P. Tony, M. Hau, C. Kessler, R. Jahns, and M. Jenett Colour Doppler ultrasound of the nailbed: an objective tool for monitoring responses to vasodilatory treatment of connective tissue disorders? Rheumatology, August 1, 2001; 40(8): 954 - 955. [Full Text] [PDF]
|
|
|
|
|
|
D. E. Furst, P. J. Clements, W. K. Wong, M. D. Mayes, F. Wigley, B. White, M. Weisman, W. Barr, L. Moreland, R. Martin, et al. Effects of the American College of Rheumatology systemic sclerosis trial guidelines on the nature of systemic sclerosis patients entering a clinical trial Rheumatology, June 1, 2001; 40(6): 615 - 622. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. R Mohler III, B. Klugherz, R. Goldman, S. E Kimmel, M. Wade, and C. M Sehgal Trial of a novel prostacyclin analog, UT-15, in patients with severe intermittent claudication Vascular Medicine, November 1, 2000; 5(4): 231 - 237. [Abstract] [PDF]
|
|
|
|
 |
|
 D. B. Badesch, V. F. Tapson, M. D. McGoon, B. H. Brundage, L. J. Rubin, F. M. Wigley, S. Rich, R. J. Barst, P. S. Barrett, K. M. Kral, et al. Continuous Intravenous Epoprostenol for Pulmonary Hypertension Due to the Scleroderma Spectrum of Disease: A Randomized, Controlled Trial Ann Intern Med, March 21, 2000; 132(6): 425 - 434. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Stumpflen, A. Ahmadi, M. Atteneder, M. Gschwandtner, S. Hofmann, T. Maca, G. Schnurer, E. Minar, and A. Stumpflen Effects of Transvenous Regional Guanethidine Block in the Treatment of Critical Finger Ischemia Angiology, February 1, 2000; 51(2): 115 - 122. [Abstract] [PDF]
|
|
|
|
|
|
G. Filaci, M. Cutolo, M. Scudeletti, C. Castagneto, L. Derchi, R. Gianrossi, F. Ropolo, P. Zentilin, A. Sulli, G. Murdaca, et al. Cyclosporin A and iloprost treatment of systemic sclerosis: clinical results and interleukin-6 serum changes after 12 months of therapy Rheumatology, October 1, 1999; 38(10): 992 - 996. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Belch Raynaud's phenomenon Cardiovasc Res, January 1, 1997; 33(1): 25 - 30. [Full Text] [PDF]
|
|
|
|
|
|
C. Bell, N. Coupland, and P. Creamer Digital Infarction in a Patient with Raynaud's Phenomenon Associated with Treatment with a Specific Serotonin Reuptake Inhibitor: A Case Report Angiology, September 1, 1996; 47(9): 901 - 903. [Abstract] [PDF]
|
|
Article
